Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/19/2812259/0/en/Processa-Pharmaceuticals-Announces-Expansion-of-NGC-Cap-Program-into-Advanced-or-Metastatic-Breast-Cancer.html

FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval

FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design

Read more at globenewswire.com

Related news for (PCSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.